Sector
PharmaceuticalsOpen
₹9.75Prev. Close
₹0Turnover(Lac.)
₹7.47Day's High
₹9.8Day's Low
₹9.752 Week's High
₹052 Week's Low
₹0Book Value
₹2.4Face Value
₹2Mkt Cap (₹ Cr.)
81.26P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 16.58 | 16.58 | 16.58 | 16.58 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 72.83 | 116.73 | 440.69 | 507.88 |
Net Worth | 89.41 | 133.31 | 457.27 | 524.46 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 276.6 | 261.38 | 569.83 | 319.39 |
yoy growth (%) | 5.82 | -54.12 | 78.41 | -25.74 |
Raw materials | -150.3 | -86.4 | -179.93 | -131.54 |
As % of sales | 54.33 | 33.05 | 31.57 | 41.18 |
Employee costs | -31.86 | -34.08 | -42.23 | -23.99 |
Y/e 31 Mar( In .Cr) | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | -20.74 | 8.85 | 173.38 | 11.34 |
Depreciation | -16.56 | -18.14 | -26.83 | -18.79 |
Tax paid | 1.57 | 1.01 | -47.04 | -3.21 |
Working capital | -97.43 | -74.68 | -7.35 | 108.09 |
Other operating items |
Y/e 31 Mar | Mar-2020 | Mar-2018 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 5.82 | -54.12 | 78.41 | -25.74 |
Op profit growth | -57.98 | -69.29 | 193.76 | -19.39 |
EBIT growth | -63.3 | -73.88 | 244.54 | -22.16 |
Net profit growth | -294.28 | -92.19 | 1,454.62 | -57.07 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 116.27 | 149.07 | 187.1 | 237.29 | 861.47 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 116.27 | 149.07 | 187.1 | 237.29 | 861.47 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.37 | 9.98 | 0.97 | 1.27 | 9.82 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,672.5 | 93.87 | 4,01,372.75 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,938 | 83.3 | 1,84,017.51 | 667 | 0.43 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,488.3 | 24.97 | 1,20,199.04 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,322.4 | 59.44 | 1,12,475.6 | 474 | 0.18 | 2,385 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,283.8 | 19.91 | 1,07,151.95 | 1,200.7 | 0.62 | 5,546.3 | 345.76 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director & CEO
Santosh Varalwar
Whole-time Director
Subhash Varalwar
Whole-time Director
V Manohar Rao
Independent Director
M Bhagavantha Rao
Whole-time Director
Sandeep Varalwar
Whole Time Director & CFO
S Raghunandan
Independent Director
V Peesapati
Company Secretary
Yugandhar Kopparthi
Additional Director
Aparna Bidarkar
Plot No 78-A,
Kolhar Industrial Area,
Karnataka - 585403
Tel: 91-8482-232045
Website: http://www.vivimedlabs.com
Email: yugandhar.kopparthi@vivimedlabs.com
1-2-285 Domalguda,
Hyderabad - 500 029
Tel: 91-040-27638111/4445
Website: www.aarthiconsultants.com
Email: info@aarthiconsultants.com
Summary
Vivimed Labs Limited was originally incorporated on September 22, 1988 as a private limited company in the name of Emgi Pharmaceuticals & Chemicals Pvt Ltd. On April 21, 1994, the company got converte...
Read More
Reports by Vivimed Labs Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.